Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

View All Documentation

934313

Sigma-Aldrich

Thalidomide-4-hydroxyacetate

≥95.0%

Szinonimák:

2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid, 2-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxyacetic acid

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)

About This Item

Tapasztalati képlet (Hill-képlet):
C15H12N2O7
CAS-szám:
1061605-21-7
Molekulatömeg:
332.26
MDL-szám:
MFCD31560477
UNSPSC kód:
12352200
NACRES:
NA.21
Forma:
powder or crystals
Teszt:
≥95.0%

ligand

thalidomide

Minőségi szint

100

Teszt

≥95.0%

Forma

powder or crystals

szín

off-white to light yellow

tárolási hőmérséklet

2-8°C

SMILES string

O=C(O)COC1=CC=CC=2C(=O)N(C(=O)C12)C3C(=O)NC(=O)CC3

Alkalmazás

A functionalized cereblon ligand for development of Thalidomide based PROTACs. Allows rapid conjugation with carboxyl linkers due to presence of amine group via peptide coupling reactions. Amenable for linker attachement via reductive amination, and a basic building block for making protein degrader library.

Technology Spotlight:

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks

Egyéb megjegyzések

Targeted Protein Degradation by Small Molecules

Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O′PROTAC): Effective Targeting of LEF1 and ERG

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Impact of linker length on the activity of PROTACs

Jogi információk

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

Piktogramok

Skull and crossbonesHealth hazard
GHS06,GHS08

Figyelmeztetés

Danger

Figyelmeztető mondatok

H301,H312,H360D

Veszélyességi osztályok

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A

Tárolási osztály kódja

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number
0000355849
0000355849
0000361659
0000344411
0000258611

Nem találja a megfelelő verziót?

Ha egy adott verzióra van szüksége, a tétel- vagy cikkszám alapján rákereshet egy adott tanúsítványra.

COA keresése

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Jingwei Shao et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(20), e2102555-e2102555 (2021-08-17)
DNA-binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand-binding
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással